Virote Sriuranpong, Ph.D.
Affiliations: | 2002 | Johns Hopkins University, Baltimore, MD |
Area:
Oncology, Molecular BiologyGoogle:
"Virote Sriuranpong"Parents
Sign in to add mentor| Stephen B. Baylin | grad student | 2002 | Johns Hopkins | |
| (Regulation of lung cancer cell growth and differentiation by notch signaling.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Sriuranpong V, Luangdilok S, Chantranuwatana P, et al. (2020) MCM4 as a prognostic biomarker of early-stage lung cancer. Journal of Clinical Oncology. 38 |
| Qin S, Chan SL, Sukeepaisarnjaroen W, et al. (2019) A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology. 11: 1758835919889001 |
| Thongprasert S, Geater SL, Clement D, et al. (2019) Afatinib in locally advanced/metastatic NSCLC harboring common mutations, after chemotherapy: a Phase IV study. Lung Cancer Management. 8: LMT15 |
| Vimolchalao V, Sakdejayont S, Wongchanapai P, et al. (2019) The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. International Journal of Clinical Oncology |
| Sitthideatphaiboon P, Santisukwongchote S, Khunsri S, et al. (2019) Paradoxical prognostic phenomenon of plasma T-cell-derived circulating DNA level in advanced non-small cell lung cancer. Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 22: 1117-1125 |
| Gray JE, Okamoto I, Sriuranpong V, et al. (2019) Tissue and Plasma Mutation Analysis in the FLAURA Trial: Osimertinib vs Comparator EGFR-TKI as First-Line Treatment in Patients with Mutated Advanced NSCLC. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Tiankanon K, Kongkam P, Luangsukrerk T, et al. (2019) IDDF2019-ABS-0171 EUS-Guided radiofrequency ablation as adjunctive treatment for unresectable pancreatic cancer versus chemotherapy alone (ERAP) Gut. 68 |
| Kongkam P, Tiankanon K, Cañones AR, et al. (2019) 385 Eus-Guided Radiofrequency Ablation Plus Chemotherapy Versus Chemotherapy Alone For Unresectable Pancreatic Cancer (Erap): Preliminary Results Of A Prospective Comparative Study Gastrointestinal Endoscopy. 89 |
| Lin CC, Taylor M, Boni V, et al. (2018) Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii413 |
| Pal SK, Rosenberg JE, Hoffman-Censits JH, et al. (2018) Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discovery |